Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $56.21M (cash outflow) rose 52.6% year over year, behind the +70.4% change in trailing-twelve-month net income. Sequentially, it rose 50.4% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$220.5M (+59.8%) for the fiscal year ending Dec 2026, a slowdown from the +102.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.21M+50.4% QoQ
- Last fiscal yearDec 2025
- -$137.95M+102.9% YoY
- LTMMar 2026
- -$157.32M+70.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +52.6% | +81.7% | +29.2 pp |
| 1 year | +102.9% | +59.8% | -43.0 pp |
| 3-year CAGR | +53.9% | +10.5% | -43.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (137.95M) USD
- Year-over-year change
- -102.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (137.95M) | -102.9% |
| FY2024 | 2024-12-31 | (68M) | -30.8% |
| FY2023 | 2023-12-31 | (51.99M) | -37.4% |
| FY2022 | 2022-12-31 | (37.85M) | — |
Net Income vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 net income of $157.32M is the 3rd largest of the 6 companies compared; the peer median is $70.36M.
- Its year-over-year change of +70.4% is the 2nd highest of 6, against a peer median of +26.1%.
- Over three fiscal years its annual growth of +53.9% compares with a peer median of +26.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $221.04M | +23.7% | — | — | |
| LTM Mar 2026 | $162.08M | +206.1% | +47.5% | 1363.9% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $157.32M | +70.4% | +53.9% | — |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $68.17M | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $40.23M | +45.6% | +34.5% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $70.36M | +26.1% | +26.9% | 704.4% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Depreciation & Amortization | 10K | 19K | 56K | 406K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 810K | 1.9M | 7.4M | 15.01M |
| Change in Working Capital | 4.95M | (9.62M) | (14.13M) | 14.81M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 2.64M | 0 |
| Other Working Capital | 4.95M | (9.62M) | (16.77M) | 14.81M |
| Other Non-Cash Items | 810K | 14.06M | (77K) | 895K |
| Operating Cash Flow | (32.08M) | (45.63M) | (74.75M) | (106.83M) |
| Capital Expenditures | (192K) | (586K) | (71K) | (280K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (318.17M) |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 62K | 0 |
| Investing Cash Flow | (192K) | (586K) | (9K) | (318.45M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 332.43M | 32.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 160K | 149K | 1.6M | 0 |
| Financing Cash Flow | 31.7M | 272.5M | 334.03M | 32.26M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (573K) | 226.28M | 259.27M | (393.03M) |
| Free Cash Flow | (32.27M) | (46.21M) | (74.82M) | (107.11M) |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.